Alpha-particle radiopharmaceutical platform with 43% ORR in NETs and melanoma activity both early-stage; registration path for VMT-NET depends on FDA alignment

Bull

Regulators accept the current dose level (4 mCi) and existing efficacy and safety data package as sufficient to proceed directly to a Phase 3 pivotal study, potentially with accelerated approval-friendly endpoints such as ORR or PFS. A lean trial design with a biomarker-selected (SSTR2+) population and favorable comparator arm could allow rapid enrollment, keeping the program within the company's cash runway extending into late 2027. The compassionate use data from Dresden and the meningioma proof-of-concept cohort could further broaden the label opportunity.

Bear

Regulators may require additional dose-optimization data, longer follow-up on overall survival, or a randomized controlled design with a demanding comparator such as 177Lu-DOTATATE (Lutathera), which would significantly expand the cost and timeline of the registration program beyond current cash runway. The 43% ORR in Cohort 2, while compelling, was investigator-assessed and single-arm, which regulators may view as insufficient without a randomized benchmark, particularly given an established standard of care in SSTR2-positive NETs.